Kapak Resmi

Safety of Therapy with Tocilizumab and Other Interleukin Inhibitors

Monoclonal antibodies directed against interleukin and interleukin receptors have been successfully used for the treatment of rheumatic diseases since 2001, and since 2020 they have been used as part of complex therapy for patients with severe COVID-19. This raises the question of safety of these pr...

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	V. I. Petrov (Yazar), A. Y. Ryazanova (Yazar), D. A. Nekrasov (Yazar), V. I. Svinukhov (Yazar), N. S. Privaltseva (Yazar)
Materyal Türü:	Kitap
Baskı/Yayın Bilgisi:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2022-04-01T00:00:00Z.
Konular:	article
Online Erişim:	Connect to this object online.
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

POLYPHARMACY IN MANAGMENT OF IN-PATIENTS WITH NOVEL CORONAVIRUS DISEASE (COVID-19)
Yazar:: V. I. Petrov, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Experience of Using Remdesivir in Patients with Novel Coronavirus Infection
Yazar:: V. I. Petrov, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
Yazar:: Aarat M Patel, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
Yazar:: Alexandra A. Taube, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Yazar:: E.I. Alexeeva, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

TOCILIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH SEVERE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Yazar:: E.I. Alexeeva, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

CLINICAL CASE OF TOCILIZUMAB THERAPY IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Yazar:: E. I. Alexeeva, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

COMPARATIVE EVALUATION OF THE EFFICIENCY AND SAFETY OF TREATING CHILDREN WITH POLYARTICULARY JUVENILE IDIOPATHIC ARTHRITIS WITH METHOTREXATE AND WITH METHOTREXATE COMBINED WITH TOCILIZUMAB
Yazar:: V. A. Kel'tsev, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
Yazar:: Daria Fomina, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19
Yazar:: V. I. Petrov, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Children with Severe Systemic Juvenile Idiopathic Arthritis: 12-month Follow-up
Yazar:: A. A. Baranov, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case
Yazar:: E. I. Alekseeva, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Experience of the Tocilizumab Application in Systemic Onset Juvenile Arthritis
Yazar:: A. V. Krasnopol'skaja, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Clinical Case of Tocilizumab Use in a Patient with Systemic Juvenile Idiopathic Arthritis
Yazar:: Y. M. Spivakovskiy, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

CLINICAL CASE OF TOCILIZUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Yazar:: O. L. Lomakina, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Yazar:: Vishnu Eshwar, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects
Yazar:: Hongjie Qian, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
Yazar:: Joly J, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Comparison of different treatment modalities of tocilizumab in children with systemic juvenile idiopathic arthritis
Yazar:: M. M. Kostik, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19
Yazar:: O. V. Zhukova, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Tocilizumab in the Treatment of Juvenile Rheumatoid Arthritis
Yazar:: V.V. Berejniy, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY
Yazar:: Ekaterina I. Alexeeva, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Tocilizumab (Actemra)
Yazar:: Martin Sheppard, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

TOCILIZUMAB IN THE TREATMENT OF CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS: ANALYSIS OF FACTORS INFLUENCING THE THERAPY EFFICIENCY IN THE LONG TERM
Yazar:: M. I. Kaleda, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
Yazar:: Espada G, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
Yazar:: A. V. Samtsov, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Clinical experience with tocilizumab in the treatment of pregnant woman with severe COVID-19
Yazar:: O. V. Riabokon, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

A HISTORY CASE OF TOCILIZUMAB USAGE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Yazar:: R. V. Denisova, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Experience of Using Tocilizumab in a Patient with Polyarticular Juvenile Rheumatoid Arthritis with Cervical Spine Lesions
Yazar:: E. A. Ligostaeva, ve diğerleri
Baskı/Yayın Bilgisi: (2015)

Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor
Yazar:: Yuan-Chiang Chung, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
Yazar:: Yilmaz S, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
Yazar:: Andrey L. Bakulev, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Interleukin-23 Inhibitors
Yazar:: Esra Adışen
Baskı/Yayın Bilgisi: (2022)

Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
Yazar:: Koné-Paut I, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
Yazar:: Hofer M, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
Yazar:: Sleptsova T, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Safety of Using Contrast Agents in Coronary Angiography in a Multidisciplinary Hospital in Volgograd
Yazar:: V. I. Petrov, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

CLINICAL AND ECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICS CONSUMPTION BY PATIENTS WITH COVID-19
Yazar:: V. I. Petrov, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Tocilizumab in the treatment of rheumatoid arthritis and beyond
Yazar:: Shetty A, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
Yazar:: Suzuki T, ve diğerleri
Baskı/Yayın Bilgisi: (2018)